AbbVie (ABBV) Invested Capital (2012 - 2026)
AbbVie (ABBV) posted quarterly Invested Capital of $65.0 billion for Q4 2025, down 3.2% year-over-year from $67.1 billion in Q4 2024, and up 3179.36% quarter-over-quarter from $2.0 billion in Q3 2025.
AbbVie (ABBV) Invested Capital (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Invested Capital for 14 consecutive years, with $65.0 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Invested Capital fell 3.2% year-over-year to $65.0 billion; the TTM figure through Mar 2026 stood at $69.0 billion (down 19.32% YoY), while the FY2025 annual figure was $65.0 billion, down 3.2% from the prior year.
- Invested Capital improved to $65.0 billion in Q4 2025 per ABBV's latest filing, from $2.0 billion in the prior quarter.
- Across five years, Invested Capital topped out at $76.7 billion in Q4 2021 and bottomed at $17.0 million in Q2 2022.
- Historically, Invested Capital has averaged $21.6 billion across 5 years, with a median of $9.2 billion in 2022.
- Annual changes were most pronounced in 2021 — Invested Capital jumped 12218.75% — and 2022, when it slumped 99.78%.
- AbbVie's Invested Capital stood at $76.7 billion in 2021, then decreased by 17.48% to $63.3 billion in 2022, then declined by 6.14% to $59.4 billion in 2023, then advanced by 13.07% to $67.1 billion in 2024, then slipped by 3.2% to $65.0 billion in 2025.
- Business Quant data shows ABBV's Invested Capital at $65.0 billion in Q4 2025, $2.0 billion in Q3 2025, and $2.0 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 11.69 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 8.34 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.83 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 32.24 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 5.45 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.41 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -7.25 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 25.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.34 Bn |
| Mar 31, 2026 | 8.33 Bn |
| Dec 31, 2025 | 65.00 Bn |
| Sep 30, 2025 | 1.98 Bn |
| Jun 30, 2025 | 2.00 Bn |
| Mar 31, 2025 | 3.77 Bn |
| Dec 31, 2024 | 67.14 Bn |
| Sep 30, 2024 | 2.00 Bn |
| Jun 30, 2024 | 12.59 Bn |
| Mar 31, 2024 | 10.19 Bn |
| Dec 31, 2023 | 59.39 Bn |
| Sep 30, 2023 | 5.11 Bn |
| Mar 31, 2023 | 2.80 Bn |
| Dec 31, 2022 | 63.27 Bn |
| Sep 30, 2022 | 9.20 Bn |
| Jun 30, 2022 | 17.00 Mn |
| Mar 31, 2022 | 9.94 Bn |
| Dec 31, 2021 | 76.67 Bn |
| Sep 30, 2021 | 1.00 Bn |
| Jun 30, 2021 | 7.88 Bn |